15 listed pharmaceutical companies disclosed 2019 performance forecast, 6 of which showed outstanding performance

[pharmaceutical network industry trends] time flies It's half a month since 2020 With the arrival of the Spring Festival, many people are busy going home for the new year, but for the pharmaceutical industry, many enterprises are busy disclosing the 2019 performance forecast According to statistics, since January, 15 listed pharmaceutical companies have disclosed the 2019 performance forecast Among them, wohua pharmaceutical and Taihe health are expected to increase their performance by about 100%, while Changchun hi tech, Zhifei biology, tiger pharmaceutical and hisic are expected to increase their performance by more than 50% Now I will take you into these six enterprises Pharmaceutical companies disclosed the 2019 performance forecast (picture source: pharma Com) Wohua pharmaceutical: management level improved, cost significantly reduced On January 9, wohua pharmaceutical released the performance forecast According to the forecast, in 2019, wohua pharmaceutical is expected to achieve a net profit of 89 million to 110 million yuan attributable to shareholders of listed companies, an increase of 95% - 142% over the same period of last year According to the data, the main business of wohua pharmaceutical is the R & D, production and sales of Chinese patent medicines for cardio cerebrovascular diseases At present, it has 144 varieties of Chinese patent medicine, covering 13 dosage forms of Chinese patent medicine According to the announcement, the main reasons for the company's performance growth are the improvement of management level, steady growth of revenue and substantial reduction of cost Taihe health: continue to strengthen market development and project undertaking, with sales scale and operating profit increasing year-on-year On January 10, Taihe health released performance forecast, which is expected to achieve a net profit of 60-68 million yuan attributable to shareholders of Listed Companies in 2019, with a year-on-year growth of 92.50% - 118.16% According to the announcement, during the reporting period, the company continued to strengthen market development and project undertaking, and the sales scale and operating profit achieved year-on-year growth It is reported that Taihe health has a monoclonal antibody radioimmunoassay targeting drug for the treatment of primary liver cancer in the field of Biopharmaceutics, and a national first-class new drug, iodometuximab injection (ricardine) Relying on these two core pharmaceutical products, Taihe health is trying to build a health pharmaceutical industry group with modern Chinese medicine as the basis and biopharmaceutical as the feature Changchun hi tech: it has implemented major asset restructuring and completed the acquisition of Jinsai pharmaceutical's equity On January 3, Changchun hi tech issued the performance forecast It is estimated that in 2019, the net profit attributable to shareholders of listed companies will be 1.610-1.812 billion yuan, an increase of 60% - 80% over the same period of last year According to the announcement, the main reasons for the growth of Changchun hi tech's performance are the growth of the income of the key holding pharmaceutical enterprises; the year-on-year rise of the settlement income of the real estate development projects; the implementation of major asset restructuring in the reporting period, and the completion of the acquisition of 29.5% minority shareholders' equity of kinsay pharmaceutical According to the data, Kinsey pharmaceutical is mainly engaged in the research, development, production and sales of biomedical products, and its main products are all kinds of recombinant human growth hormone products As for the main reasons for the growth of Changchun hi tech performance, it is disclosed in the announcement that it is the income growth of key pharmaceutical enterprises holding shares; the settlement income of real estate development projects has increased year on year; during the reporting period, major asset restructuring has been carried out, and the acquisition of 29.5% minority shareholders' equity of Jinsai pharmaceutical has been completed Zhifei biology: focus on vaccines and biological products, and steadily advance various works On the evening of January 3, Zhifei biology released the performance forecast According to the forecast, Zhifei biology expects to achieve a net profit of 2.250-2.540 billion yuan attributable to shareholders of Listed Companies in 2019, an increase of 55% - 75% over the same period of last year According to the data, the main business of Zhifei biology is the R & D, production and sales of vaccines and biological products For the performance growth, the relevant person in charge said that in 2019, Zhifei biology continued to focus on the research and development, production, sales, promotion, distribution and import vaccine agency of vaccines and biological products, with steady progress in various works, smooth progress in product sales and better completion of the annual production and operation plan Tag Pharma: a leading clinical cro in China, with continuous growth of its main business On January 10, tag Pharma issued a performance forecast It is expected to achieve a net profit of 795-902 million yuan attributable to shareholders of Listed Companies in 2019, an increase of 68.45% - 91.13% year on year According to the data, tag pharmaceutical is a contract research organization (CRO) focusing on providing professional services for the whole process of clinical trials for new drug research and development, mainly providing professional services for innovative drugs, medical devices and biotechnology related products for domestic and foreign pharmaceutical and medical device innovation enterprises As for the reasons for the performance change, the announcement disclosed that during the reporting period, the company's main business continued to grow, and it is expected that the operating revenue in 2019 and the net profit attributable to the shareholders of the listed company will increase compared with the same period of last year Hisense: engaged in new drug research and development, with a steady year-on-year growth in revenue and sales volume On January 13, Hisense released a performance forecast According to the forecast, Hisense expects to achieve a net profit of 500 million to 520 million yuan attributable to shareholders of Listed Companies in 2019, an increase of 50.05% to 56.05% year-on-year According to the data, hispec is mainly engaged in new drug research and development, manufacturing, sales and other businesses Its products are sold in the domestic market, involving liver disease, parenteral nutrition, depression, antibiotics and other fields, including polyene phosphatidylcholine injection, fat soluble vitamin series for injection, dorasetron mesylate injection, etc As for the reason of this performance change, hisilico said that the net profit attributable to the shareholders of the listed company increased year-on-year, mainly due to the relatively stable growth of operating revenue and sales volume in the current period.